Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05650307 · ClinicalTrials.gov registry record

CV Imaging of Metabolic Interventions

A clinical trial of Heart Failure and Cardiovascular Diseases, sponsored by The Cleveland Clinic.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT05650307 is a study of Heart Failure and Cardiovascular Diseases that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 150 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05650307, a study of Heart Failure and Cardiovascular Diseases, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Cardiovascular disease is the leading cause of death worldwide. It is becoming clearer that heart failure (HF) is closely associated with body's metabolism. Even before the heart becomes weaker, it responds to the stresses by changing the fuels it burns, which results in a reduction in the heart's metabolic efficiency that worsens the heart's condition. Since the heart burns so much fuel and consumes fats and carbohydrates along with other available substrates, any changes in its metabolic efficiency could impact metabolism throughout the body. Specifically, HF is characterized by limited flexibility in substrate utilization leading to an overall energetic deficit. Such energetic deficit is associated with progressive remodeling and alter cardiac hemodynamics. For example, obesity is a widely known risk factor for cardiovascular disease likely lie in how the heart handles energy (substrate utilization and energetics). One commonly recommended treatment for cardiovascular disease, especially coronary artery disease (CAD) or congestive heart failure (CHF), is cardiac rehabilitation. Cardiac rehabilitation for symptomatic cardiovascular disease has been shown to promote a healthy lifestyle, improve physical health and reduce cardiovascular death iii with an apparent dose-dependent response. Participation results in a reduced risk of hospitalization and revascularization procedures, and improved functional status in randomized controlled trials. Thus, cardiac rehabilitation is recommended for individuals with symptomatic CAD or CHF by the American College of Cardiology and American Heart Association. In addition, exercise training in preclinical animal models mirroring the exercise component of cardiac rehabilitation routines have shown increased myocardial regeneration and cardioprotective molecular effects ameliorating adverse myocardial remodeling. Despite these benefits, there is vast heterogeneity in the efficiency of cardiac rehabilitation on the individual level

Interventions

  • DIAGNOSTIC_TEST MRI

Study Locations (1)

Ohio

  • Cardiovascular Innovation Research Center - Cleveland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-09-09
Est. Completion 2027-09-09

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT05650307

The ClinicalTrials.gov registry entry for NCT05650307 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (93% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.

NCT05650307 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05650307 about?

NCT05650307 is a clinical study titled "CV Imaging of Metabolic Interventions". Cardiovascular disease is the leading cause of death worldwide. It is becoming clearer that heart failure (HF) is closely associated with body's metabolism. Even before the heart becomes weaker, it responds to the stresses by changing the fuels it burns, which results in a reduction in the heart's m...

What is the current status of trial NCT05650307?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-09-09. Estimated completion is 2027-09-09.

What conditions does trial NCT05650307 study?

This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Bariatric Surgery Candidate.

What interventions are being tested in trial NCT05650307?

The interventions under investigation include: MRI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05650307?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05650307 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.